{"id":16922,"date":"2018-06-07T07:15:11","date_gmt":"2018-06-07T07:15:11","guid":{"rendered":"https:\/\/arisglobal.com\/bkp-site\/?p=16922"},"modified":"2018-06-07T07:15:11","modified_gmt":"2018-06-07T07:15:11","slug":"webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test","status":"publish","type":"post","link":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/","title":{"rendered":"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry"},"content":{"rendered":"<p>The Chinese Federal Drug Authority (CFDA) regulations are changing and that brings both challenges and opportunities. The introduction of the E2B(R3) mandate pushed the local Chinese pharmaceutical market to scramble.\u00a0 There might be breathing room now with the update to accept E2B(R2) submissions for another year, but the clock is ticking.<\/p>\n<p>Innovative solutions for the pharmaceutical industry are necessary to meet the CFDA regulation for pharmacovigilance and clinical safety, along with full compliance with E2B(R3) guidelines with complete localization.\u00a0 Forward thinking Chinese organizations are looking to future proof their PV solutions, while maintaining continuous compliance.<\/p>\n<p>By adopting newer technologies that incorporate machine learning and artificial intelligence, systems can be future-proofed and meet the challenges head-on. This webinar will look at the impact of the latest CFDA announcement on ICSR reporting as well as existing and expected submissions.<\/p>\n<p><strong>This webinar:<\/strong><\/p>\n<ul>\n<li>Addresses the latest CFDA regulations announcement and the impact on domestic and global companies<\/li>\n<li>Explores What is required to be compliant with the latest regulations<\/li>\n<li>Provide a \u2018first hand\u2019 view into what a compliant, AI driven product can do \u2013 in localized language.<\/li>\n<li>Discuss cognitive computing technologies available<\/li>\n<\/ul>\n<p>The Chinese Federal Drug Authority (CFDA) regulations are changing and that brings both challenges and opportunities. The introduction of the E2B(R3) mandate pushed the local Chinese pharmaceutical market to scramble.\u00a0 There might be breathing room now with the update to accept E2B(R2) submissions for another year, but the clock is ticking.<\/p>\n<p>Innovative solutions for the pharmaceutical industry are necessary to meet the CFDA regulation for pharmacovigilance and clinical safety, along with full compliance with E2B(R3) guidelines with complete localization.\u00a0 Forward thinking Chinese organizations are looking to future proof their PV solutions, while maintaining continuous compliance.<\/p>\n<p>By adopting newer technologies that incorporate machine learning and artificial intelligence, systems can be future-proofed and meet the challenges head-on. This webinar will look at the impact of the latest CFDA announcement on ICSR reporting as well as existing and expected submissions.<\/p>\n<p><strong>This webinar:<\/strong><\/p>\n<ul>\n<li>Addresses the latest CFDA regulations announcement and the impact on domestic and global companies<\/li>\n<li>Explores What is required to be compliant with the latest regulations<\/li>\n<li>Provide a \u2018first hand\u2019 view into what a compliant, AI driven product can do \u2013 in localized language.<\/li>\n<li>Discuss cognitive computing technologies available<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The Chinese Federal Drug Authority (CFDA) regulations are changing and [&hellip;]<\/p>\n","protected":false},"author":27,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-16922","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.4 (Yoast SEO v23.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry | ArisGlobal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry\" \/>\n<meta property=\"og:description\" content=\"The Chinese Federal Drug Authority (CFDA) regulations are changing and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\" \/>\n<meta property=\"og:site_name\" content=\"ArisGlobal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LifeSphereAG\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-07T07:15:11+00:00\" \/>\n<meta name=\"author\" content=\"Mladen Prenc\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mladen Prenc\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\"},\"author\":{\"name\":\"Mladen Prenc\",\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974\"},\"headline\":\"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry\",\"datePublished\":\"2018-06-07T07:15:11+00:00\",\"dateModified\":\"2018-06-07T07:15:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arisglobal.com\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\",\"url\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\",\"name\":\"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry | ArisGlobal\",\"isPartOf\":{\"@id\":\"https:\/\/www.arisglobal.com\/#website\"},\"datePublished\":\"2018-06-07T07:15:11+00:00\",\"dateModified\":\"2018-06-07T07:15:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arisglobal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arisglobal.com\/#website\",\"url\":\"https:\/\/www.arisglobal.com\/\",\"name\":\"ArisGlobal\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arisglobal.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arisglobal.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arisglobal.com\/#organization\",\"name\":\"LifeSphere\",\"url\":\"https:\/\/www.arisglobal.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"LifeSphere\"},\"image\":{\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LifeSphereAG\/\",\"https:\/\/www.linkedin.com\/products\/aris-global-lifesphere\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974\",\"name\":\"Mladen Prenc\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry | ArisGlobal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/","og_locale":"en_US","og_type":"article","og_title":"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry","og_description":"The Chinese Federal Drug Authority (CFDA) regulations are changing and [&hellip;]","og_url":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/","og_site_name":"ArisGlobal","article_publisher":"https:\/\/www.facebook.com\/LifeSphereAG\/","article_published_time":"2018-06-07T07:15:11+00:00","author":"Mladen Prenc","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mladen Prenc","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#article","isPartOf":{"@id":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/"},"author":{"name":"Mladen Prenc","@id":"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974"},"headline":"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry","datePublished":"2018-06-07T07:15:11+00:00","dateModified":"2018-06-07T07:15:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/www.arisglobal.com\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/","url":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/","name":"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry | ArisGlobal","isPartOf":{"@id":"https:\/\/www.arisglobal.com\/#website"},"datePublished":"2018-06-07T07:15:11+00:00","dateModified":"2018-06-07T07:15:11+00:00","breadcrumb":{"@id":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.arisglobal.com\/uncategorized\/webinar-pharmacovigilance-china-current-updates-challenges-solutions-industry-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arisglobal.com\/"},{"@type":"ListItem","position":2,"name":"Pharmacovigilance in China \u2013 Current Updates, Challenges and Solutions for the Industry"}]},{"@type":"WebSite","@id":"https:\/\/www.arisglobal.com\/#website","url":"https:\/\/www.arisglobal.com\/","name":"ArisGlobal","description":"","publisher":{"@id":"https:\/\/www.arisglobal.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arisglobal.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arisglobal.com\/#organization","name":"LifeSphere","url":"https:\/\/www.arisglobal.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"LifeSphere"},"image":{"@id":"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LifeSphereAG\/","https:\/\/www.linkedin.com\/products\/aris-global-lifesphere\/"]},{"@type":"Person","@id":"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974","name":"Mladen Prenc"}]}},"_links":{"self":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/posts\/16922"}],"collection":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/comments?post=16922"}],"version-history":[{"count":0,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/posts\/16922\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/media?parent=16922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/categories?post=16922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/tags?post=16922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}